Study of pulmonary sequelae in patients with anti-MDA-5 antibody-positive dermatomyositis who were able to survive for a long period of time.

Study of pulmonary sequelae in patients with anti-MDA-5 antibody-positive dermatomyositis who were able to survive for a long period of time. - Study of pulmonary sequelae in patients with anti-MDA-5 antibody-positive dermatomyositis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054981

Enrollment

Registered

2024-07-25

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-MDA-5 antibody-positive dermatomyositis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Medical information on patients diagnosed with dermatomyositis between January 1, 2008 and December 31, 2022 in the Department of Respiratory, Neurological and Collagen Diseases, Kurume University Hospital will be used. Among them, the number of anti-MDA-5 antibody-positive cases that could be saved is 28. All patients will be enrolled in the study except those who refuse to participate, which will be made public on the website in an opt-out format. Selection criteria: Persons who meet all of the following criteria will be selected 1. Aged 20 years or older 2. Those diagnosed with dermatomyositis who test positive for anti-MDA-5 antibodies 3. Those who have survived past the acute phase of the disease and have survived for 2 years after the onset of the disease

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria shall be excluded from eligibility Patients who meet any of the following criteria will not be selected even if they meet the selection criteria 1. Those who are deemed inappropriate as research subjects by the principal investigator and the research coordinator.

Design outcomes

Primary

Measure	Time frame
ow oxygenation, serological data, pulmonary function tests, and chest CT imaging findings improve in surviving patients with anti-MDA-5 antibody-positive dermatomyositis.	—

Secondary

Measure	Time frame
Can the treatment be terminated?	—

Countries

Japan

Contacts

Public ContactMasaki Tominaga

Kurume University School of Medicine Department of Community Medicine

tominaga_masaki@med.kurume-u.ac.jp0942317586

Outcome results